US4088747A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Phenolic amino-carboxylic acid radiopharmaceuticals
Assignee: Australian Atomic Energy Commission
•
Filing: 1976-02-03
•
Granted: 1978-05-09
•
Expires: 1996-02-03
Abstract
Abstract A radiopharmaceutical for use on animals including human beings comprises a metal chelate in which the chelating agent is a phenolic amino carboxylic acid or an alkali salt thereof, and the metal is a pharmaceutically acceptable radio isotope such as technetium-99m. The chelating agent may be advantageously an ethylenediamine carboxylic acid or its salt having a phenolic group at each end of the molecule such as EDDHA and HBED or alternatively the phenolic amino carboxylic acid or its salt may have a single phenolate group such as HBG or HBS. The pharmaceutical has a balance of lipo-solubility and water-solubility to permit hepato-biliary imaging.
Inventors
- 👤 Frederick C. Hunt
- 👤 John G. Wilson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 05:18
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0474; A61K51/0478; A61K2121/00; A61K2123/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
56 words
A radiopharmaceutical for imaging hepatobiliary function comprising a lipo-soluble metal chelate in which the metal is a pharmaceutically acceptable radio isotope for an animal and the chelating agent is selected from the group consisting of an ethylene diamine di(hydroxy phenyl carboxylic acid), a salt thereof, a di(hydroxy benzyl) ethylene diamine dicarboxylic acid and a salt thereof.
Claim 2
Dependent Claim
56 words
A radiopharmaceutical for imaging hepatobiliary function comprising a lipo-soluble metal chelate in which the metal is a pharmaceutically acceptable radio isotope for an animal and the chelating agent is selected from the group consisting of an ethylene diamine di(hydroxy phenyl carboxylic acid), a salt thereof, a di(hydroxy benzyl) ethylene diamine dicarboxylic acid and a salt thereof.
Claim 3
Dependent Claim
59 words
A radiopharmaceutical as claimed in claim 1, wherein the chelating agent is selected from the group consisting of ##STR5## wherein X is hydrogen, a halogen or an alkyl group, ##STR6## wherein X is hydrogen, a halogen or an alkyl group, (3) an alkali metal salt of compound (1) above and (4) an alkali metal salt of compound (2) above.
Claim 4
Dependent Claim
54 words
A radiopharmaceutical for imaging hepatobiliary function comprising a lipo-soluble metal chelate in which the metal is a pharmaceutically acceptable radio isotope for an animal and the chelating agent is a phenolic amino-carboxylic acid or a salt thereof said chelating agent having a single phenolic group, having a balance of both lipo-soluble and water-soluble properties.
Claim 5
Dependent Claim
54 words
A radiopharmaceutical for imaging hepatobiliary function comprising a lipo-soluble metal chelate in which the metal is a pharmaceutically acceptable radio isotope for an animal and the chelating agent is a phenolic amino-carboxylic acid or a salt thereof said chelating agent having a single phenolic group, having a balance of both lipo-soluble and water-soluble properties.
Claim 6
Dependent Claim
37 words
A radiopharmaceutical as claimed in claim 3, wherein the chelating agent is selected from the group consisting of hydroxybenzyl glycine, hydroxybenzyl sarcosine, an alkali metal salt of hydroxybenzyl glycine and an alkali metal salt of hydroxybenzyl sarcosine.
Claim 7
Dependent Claim
21 words
A radiopharmaceutical as claimed in claim 4, wherein the chelating agent has alkyl or halogen substituents in the phenolic ring thereof.
Claim 8
Dependent Claim
16 words
A radiopharmaceutical as claimed in claim 2, wherein the chelating agent is ethylene-bis (α-imino-2-hydroxy-5-chlorophenyl acetic acid).
Claim 9
Dependent Claim
21 words
A radiopharmaceutical as claimed in claim 4, wherein the chelating agent is selected from the group consisting of N-(o-hydroxybenzyl)glycine and N-(o-hydroxybenzyl)sarcosine.
Claim 10
Dependent Claim
22 words
A radiopharmaceutical as claimed in claim 2, wherein the radio isotope is technetium-99m, and the radiopharmaceutical is a complex of stannous tin.
Claim 11
Dependent Claim
19 words
A radiopharmaceutical as claimed in claim 2, wherein the chelating agent has halogen substituents in the phenolic ring thereof.
Claim 12
Dependent Claim
13 words
A radiopharmaceutical as claimed in claim 9, wherein said halogen substituent is bromine.
References Cited (Backward Citations)
USRE23905E
Cited
US2624757A
Cited
FR1431697A
Cited
US3509208A
Cited
US3833590A
Cited
US3749556A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-05-08 | 1981-11-07 | 1982-05-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-05-08 | 1985-11-07 | 1986-05-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-05-08 | 1989-11-07 | 1990-05-09 | $7700.00 | Window Closed / Lapsed |